Meningitis diagnosis, treatment, and outcomes in rural, northern Uganda
2015–2024
Bibliographic Data
| ID | 19592886 |
|---|---|
| Authors | Abigail Link (0000-0003-2209-1946, Lira Hospital, corresponding author), Mark Okwir (0000-0001-8452-313X, Lira Hospital), Betty Nabongo (Lira Hospital), Fred Okello (Lira Hospital), Jimmy Alal (Lira Hospital), David B Meya (0000-0002-8854-0321), David Meya (Lira Hospital), Paul R Bohjanen (0000-0002-2772-3597, University of Minnesota) |
| Editors | Mustafa A Barbhuiya |
| Year | 2026 |
| Volume | 6 |
| Issue | 1 |
| Pages | e0005800 |
| Publication date | 2026-01-12 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | PLOS Global Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2767-3375 • E-ISSN: 2767-3375 |
| Publisher | Public Library of Science (PLoS) (PUBLISHER) |
| DOI | 10.1371/journal.pgph.0005800 |
| PMID | 41525300 |
| OpenAlex | W7123340534 |
| Language | EN |
| References cited | 43 |
Meningitis affects over 2.5 million people worldwide, primarily within resource-limited regions of the meningitis belt of Africa. In 2017, we implemented a cryptococcal meningitis (CM) diagnosis and treatment program (CM-DTP) designed to improve CM outcomes. In 2021, a meningitis diagnosis and treatment program (MEN-DTP) began to include all etiologies of meningitis to assess the impact of expanded diagnosis and treatment of meningitis. We conducted a retrospective study utilizing clinical records from 1443 adult patients admitted to Lira Regional Referral Hospital (LRRH) over three time periods between 2015–2024. Group 1 included 321 patients in a historical control group; Group 2 consisted of 890 patients during the CM-DTP and Group 3 included 232 patients during the MEN-DTP. Group 1 received routine meningitis care, Group 2 received testing and treatment focused on CM, and Group 3 received expanded diagnostic testing, including gram stain, culture, PCR- and antigen-based testing. Meningitis diagnosis and in-hospital mortality outcomes were assessed to evaluate our programs. A confirmed meningitis etiology was found in 13.7% in Group 1, 20.7% in Group 2, and 42.2% in Group 3. In Group 3, confirmed etiologies were identified based on culture (n = 30), Pastorex LA (n = 23), BioFire PCR (n = 56), GeneXpert Ultra (n = 14), and serum or CSF CrAg LFA (n = 53). Overall, more confirmed etiologies of meningitis were identified among people living with HIV (PLWH) (n = 319) compared to those without HIV (n = 22) in Group 3. Antibiotic use increased with pre-admission antibiotic use doubling from Group 1 to Group 3 (10.6% to 27.2%). Compared to Group 1, mortality improved in Groups 2 and 3. Overall, PLWH had increased mortality compared to those without HIV (32.4% vs. 13.3%). Introduction of molecular diagnostics increased meningitis diagnoses and improved outcomes, particularly in those with CM. MEN-DTP increased confirmed diagnoses, yet half remained undiagnosed, supporting investigation of deep sequencing technologies
Etiology · Group B · Medical record · Meningitis · Meningococcal meningitis · Referral · Retrospective cohort study · Viral meningitis · Bacterial Infections and Vaccines · Fungal Infections and Studies · Nail Diseases and Treatments
| Highly cited | No |
|---|